Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials

Adrienne G Randolph, Deborah J Cook, Calle A Gonzales, Maureen Andrew

Abstract

Objective: To evaluate the effect of heparin on duration of catheter patency and on prevention of complications associated with use of peripheral venous and arterial catheters.

Design: Critical appraisal and meta-analysis of 26 randomised controlled trials that evaluated infusion of heparin intermittently or continuously. Thirteen trials of peripheral venous catheters and two of peripheral arterial catheters met criteria for inclusion.

Main outcome measures: Data on the populations, interventions, outcomes, and methodological quality.

Results: For peripheral venous catheters locked between use flushing with 10 U/ml of heparin instead of normal saline did not reduce the incidence of catheter clotting and phlebitis or improve catheter patency. When heparin was given as a continuous infusion at 1 U/ml the risk of phlebitis decreased (relative risk 0.55; 95% confidence interval 0.39 to 0.77), the duration of patency increased, and infusion failure was reduced (0.88; 0.72 to 1.07). Heparin significantly prolonged duration of patency of radial artery catheters and decreased the risk of clot formation (0.51; 0.42 to 0.61).

Conclusions: Use of intermittent heparin flushes at doses of 10 U/ml in peripheral venous catheters locked between use had no benefit over normal saline flush. Infusion of low dose heparin through a peripheral arterial catheter prolonged the duration of patency but further study is needed to establish its benefit for peripheral venous catheters.

Introduction

Almost all patients admitted to hospital require a peripheral intravenous catheter to provide access for administration of drugs and fluids and parenteral nutrition. In addition, many critically ill patients require arterial catheterisation for haemodynamic monitoring and blood sampling. Maintenance of the patency of these indwelling catheters is important for minimising patients’ discomfort and the expense associated with replacement. Vascular thrombosis, visible scarring, and infection related to the catheter are complications associated with use of these indwelling vascular devices.

The anticoagulant properties of heparin led clinicians to use heparin flushes or heparinised infusion in an attempt to prevent thrombus formation and to prolong the duration of catheter patency. The effective dose of heparin, however, has not been clearly established for venous and arterial catheters. Two meta-analyses evaluating use of heparin flush solutions for peripheral intermittent infusion devices concluded that the effect of heparin flushes was equivalent to that of 0.9% sodium chloride flushes. Both meta-analyses combined the results of controlled and uncontrolled trials, and pooled the results of randomised controlled trials and non-randomised controlled trials. Despite its beneficial antithrombotic effects, decreasing unnecessary exposure to heparin is important to minimise the complications resulting from sensitisation. Autoimmune mediated thrombocytopenia induced by heparin occurs in about 3% of patients exposed to unfractionated heparin, which greatly
increases the risk of thrombotic events. Heparin induced thrombocytopenia is a risk even in newborns. Other risks of heparin use include allergic reactions and the potential for bleeding complications after multiple, unmonitored heparin flushes.

A large percentage of heparin exposure in patients in hospital is through heparin use in peripheral venous catheters. If the risks associated with heparin use are considered what is the benefit of using heparin in peripheral venous or arterial access devices? Individual trials of heparin in peripheral venous catheters are contradictory, and there are no systematic reviews assessing various heparin dosing strategies for arterial catheters. We therefore conducted this systematic review to resolve and synthesise the conflicting literature. We have critically appraised the clinical trials evaluating use of heparin in continuous and intermittent infusion solutions on the duration of patency of peripheral venous and arterial catheters and on phlebitic complications.

Methods

Study identification

Trials included in this review were identified by cross referencing the following MeSH terms from Medline from 1966 to April 1997: “catheterisation” and “catheters, indwelling” and “heparin” with “randomisation,” “random allocation,” “randomised controlled trial(s), randomised response technique,” and “controlled clinical trials, randomised.” Embase was searched from 1974 through 1996 by using the search terms “catheter” and “catheterisation, intravascular, random,” and “heparin.” After examining the full manuscripts of all abstracts deemed potentially relevant we reviewed the reference lists of each retrieved article and obtained the manuscript of any reference considered to be a randomised controlled trial. The trials included in two meta-analyses were retrieved. Package inserts from catheter kits were searched for references regarding published and unpublished data. We also contacted companies manufacturing heparin bonded catheters regarding other unpublished and published randomised controlled trials. In addition, we hand searched the National Intravenous Therapy Association Journal from 1985 to 1992.

Study selection

The following selection criteria were used to identify studies for inclusion in this analysis: study design—randomised controlled clinical trial; population—adult or paediatric patients; intervention—heparin infused through the catheter via intermittent or continuous flush versus a control group with no heparin; outcomes—catheter patency, catheter related phlebitis, catheter thrombus, infusion failure.

We excluded studies in which over 40% of patients were excluded from analysis after randomisation.

Data abstraction

Data abstraction was conducted by two investigators; disagreement was resolved by consensus. To evaluate agreement we calculated a quadratic weighted $k$ for each item. Data on the number of catheters or the numbers of patients, or both, were abstracted in the form in which they were reported. Catheters were the unit of analysis when data were pooled because this was the way that most results were reported. We tried to contact authors to provide further information when the data necessary for critical appraisal or analysis, or both, were missing or unclear.

Definitions

The following definitions of terms were used. Duration of catheter patency was the number of hours the catheters were in place. Loss of patency was removal of the catheter because of inability to flush it. Catheter thrombus referred to a clot adherent to or occluding the catheter. Catheter related phlebitis indicated the presence of any one or more of the following: pain, erythema, induration, or a palpable venous cord at the catheter site. Infusion failure was loss of patency, phlebitis, or infiltration resulting in premature removal of the catheter.

Data analysis

We combined data to estimate the relative risks and associated 95% confidence intervals across studies by using the DerSimonian and Laird random effects model. We tested for heterogeneity (major differences in the apparent effect of the interventions across studies) by using the method proposed by Fleiss. We have reported tests of heterogeneity of variance in the results only when they were significant ($P < 0.05$).

A priori we decided to analyse the data in clinically relevant categories on the basis of similar heparin dosing strategies when sufficient data were available. This was possible for heparin flush of peripheral intravenous catheters at the most common dose of 10 U/ml and at 100 U/ml used intermittently at a minimum of 6 to 12 hour intervals. We separately examined the effect of adding 1 U/ml of heparin to continuous infusions. Because heparin bonding is only on the outside of some catheters and lasts from 30 minutes to 48 hours depending on the type of bonding used (personal communications, technical support staff, Cook, Arrow, Medcomp, Abbott, and Baxter catheter manufacturing companies) we excluded trials of heparin bonding.

Results

Study identification and selection

Twenty six trials of heparin use in peripheral venous catheters were identified in which random assignment was used, and 13 were included—12 published trials and one unpublished (FD Craig and SR Anderson, Harrison Methodist Fort Worth Hospital, personal communication). Two trials of heparin use in peripheral arterial catheters were identified in which random assignment was used and both were included. Three trials claiming random allocation that actually used alternate assignment or assignment by odd-even hospital number were excluded. Five trials were excluded that randomised by hospital unit or wards instead of individual patient because only two units were randomised and a before-after design was applied within each unit. One randomised study was excluded because all patients received 5000 U heparin subcutaneously for prophylaxis of deep
venous thrombosis. Three randomised studies were excluded because more than 40% of observations were not reported after randomisation. One randomised study was excluded because only half the patients were randomised and the rest were allocated to treatment arms at the discretion of the physician. The authors of one unpublished trial were unable to provide the necessary primary data (N Bell, D Brown, L Poon, Eden Hospital Medical Centre, California, personal communication). One randomised trial of peripheral venous catheters was performed in patients treated with cephalothin and another was done in patients receiving a lignocaine infusion, both of which are associated with higher rates of phlebitis leading us to exclude these trials from our analysis. We were unable to include the results of one unpublished randomised study because they reported the number of events per patient, many of whom had more than one catheter, and the primary author could not re-extract the data (A Kasparek, J Wenger, R Feldt, Mercy Medical Centre, Iowa, personal communication).

Trial characteristics and assessment of quality

The populations, interventions, number of patients, number of catheters, catheter gauges used, and methodological characteristics of the studies included in the final analysis are described in table 1. For peripheral venous catheters, intermittent heparin flushes varied from 10 U/ml to 100 U/ml and continuous heparin infusion was 1 U/ml. In the trial by Moclair et al all patients received a glyceryl trinitrate transdermal patch and twice daily application of hydrocortisone cream to the infusion site in an attempt to prolong vein survival and decrease phlebitis. The doses of heparin in trials evaluating continuous flush in arterial catheters varied, and the actual dose was not reported in the largest trial as it was an effectiveness study of any amount of heparin versus no heparin.

Four trials evaluated multiple catheter insertions in a single patient. Two of these trials evaluated intermittent heparin flushes at concentrations of 10 U/ml and 100 U/ml showed no effect on duration of catheter patency. Two trials showed that heparin added to the infusion to make a concentration

<table>
<thead>
<tr>
<th>Author</th>
<th>Population</th>
<th>Heparin</th>
<th>Catheters</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moclair et al, 1991</td>
<td>16 Adults, surgical</td>
<td>1 U/ml infused</td>
<td>16</td>
<td>Double</td>
</tr>
</tbody>
</table>

Table 1 Study design of randomised trials of heparin infusion and bonding


\[
\text{(Author Heparin Patency duration (hours) Difference (hours) for heparin \text{- control})}
\]

<table>
<thead>
<tr>
<th>Author</th>
<th>Heparin</th>
<th>Patency duration (hours)</th>
<th>Difference (hours) for heparin \text{- control}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moclair et al, 1991</td>
<td>1 U/ml infused</td>
<td>38.2 (40)</td>
<td>35.4 (30)</td>
</tr>
<tr>
<td>Daniel et al, 1973</td>
<td>1 U/ml infused</td>
<td>88.5</td>
<td>57.6</td>
</tr>
<tr>
<td>Alpin et al, 1984</td>
<td>1 U/ml infused</td>
<td>58.7 (45)</td>
<td>26.1 (20)</td>
</tr>
<tr>
<td>Wright et al, 1980</td>
<td>1 U/ml infused</td>
<td>9±2</td>
<td>4±1</td>
</tr>
</tbody>
</table>

*Flush solution (control or heparin) used after medications in addition to or in place of scheduled flush.
†Authors report P<0.05.
‡Medians.
of 1 U/ml effectively prolonged peripheral venous catheter patency\textsuperscript{5-7}, and two trials showed non-significant trends in the direction of benefit.\textsuperscript{10-17} The results could not be pooled because not all investigators reported the standard deviation around the mean and some reported the median. In peripheral arterial catheters, heparin significantly prolonged the duration of catheter patency in two trials,\textsuperscript{22,23} although investigators reported the percentage of catheters patent at 72 hours (4 U/ml normal saline; 90% of heparin catheters versus 79% of control catheters; difference 11%; $P < 0.05$) and 96 hours (variable dose; 86% versus 52%; difference 34%; $P < 0.01$) and not the average number of hours catheters were patent.

### Catheter clotting and loss of patency

Figure 1 shows that use of 10 U intermittent heparin flushes had no effect on catheter clotting compared with normal saline when the results of two trials were pooled (FD Craig and SR Anderson, Harrison Methodist Fort Worth Hospital, personal communication, and Shoaf and Oliver\textsuperscript{12}). At doses of 100 U/ml flushed every 6 or 8 hours heparin was associated with a significantly lower loss of catheter patency when the results of two trials were pooled.\textsuperscript{15,16} Heparinised infusion significantly decreased loss of patency in arterial catheters when the results of two trials were pooled.\textsuperscript{22,23}

### Infusion failure

Figure 2 shows that use of intermittent 10 U heparin flushes had no effect on infusion failure rates for peripheral intravenous catheters when the results of two trials were pooled (FD Craig and SR Anderson, Harrison Methodist Fort Worth Hospital, personal communication, and Shoaf and Oliver\textsuperscript{12}). Addition of heparin at a concentration of 1 U/ml to the infusion was associated with a reduced risk of infusion failure when the results of three trials were pooled.\textsuperscript{10,17,20}

### Catheter related phlebitis

Figure 3 shows that there was a significant difference in the risk of phlebitis when the results of three trials of 10 U/ml intermittent heparin flushes versus normal saline were pooled (FD Craig and SR Anderson, Harri-

### Table: Relative risks (95% confidence intervals) for catheter clot formation in and loss of patency of peripheral venous and arterial catheters according to treatment with or without heparin.

<table>
<thead>
<tr>
<th>Author</th>
<th>Heparin</th>
<th>Relative risk (95% CI)</th>
<th>Clotting or loss of patency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Heparin benefit</td>
</tr>
<tr>
<td>Peripheral venous catheters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Craig et al, 1991</td>
<td>10 U 8 hourly</td>
<td>0.89 (0.23 to 3.49)</td>
<td></td>
</tr>
<tr>
<td>(personal communication)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shoaf et al, 1992\textsuperscript{12}</td>
<td>10 U 8 hourly</td>
<td>1.15 (0.53 to 2.46)</td>
<td></td>
</tr>
<tr>
<td>Hamilton et al, 1988\textsuperscript{15}</td>
<td>100 U 8 hourly</td>
<td>0.73 (0.32 to 1.67)</td>
<td></td>
</tr>
<tr>
<td>Meyer et al, 1995\textsuperscript{16}</td>
<td>100 U 6 hourly</td>
<td>0.44 (0.26 to 0.77)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Common relative risk</td>
<td>1.08 (0.55 to 2.10)</td>
<td></td>
</tr>
<tr>
<td>Peripheral arterial catheters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clifton et al, 1991\textsuperscript{26}</td>
<td>4 U/ml normal saline</td>
<td>0.43 (0.14 to 1.35)</td>
<td></td>
</tr>
<tr>
<td>American Association of Critical Care Nurses, 1993\textsuperscript{28}</td>
<td>Any in infusion</td>
<td>0.51 (0.42 to 0.61)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Common relative risk</td>
<td>0.52 (0.33 to 0.83)</td>
<td></td>
</tr>
</tbody>
</table>

### Figure 1: Relative risks (95% confidence intervals) for catheter clot formation in and loss of patency of peripheral venous and arterial catheters according to treatment with or without heparin. Last two columns are numbers of catheters with clots/total number of catheters.

### Figure 2: Relative risks (95% confidence intervals) for failure of infusion in peripheral venous catheters according to treatment with or without heparin. Last two columns are numbers of catheters with failure of infusion/total number of catheters.
son Methodist Fort Worth Hospital, personal communication). When the results of two trials of 100 U/ml of intermittent heparin flush were pooled, phlebitis was significantly decreased. The test of homogeneity, however, was significant (P = 0.0006) for the decreased risk of phlebitis, with one trial that used 100 U/ml every 6 hours showing a much larger but non-significant trend in the direction of heparin being beneficial than the trial that used 100 U/ml every 8 hours. When the data from seven trials of heparin at concentrations of 1 U/ml infusion flushed continuously through the catheter were pooled (see figure 2) there was a significant decrease in phlebitis with use of heparin.

Discussion

Use of heparin as an antithrombotic agent in catheters has been widespread for over 20 years. Despite almost universal use, the benefit of heparin has not been firmly established. Half of the available trials claiming to be randomised had to be excluded because of quality considerations or the presence of potentially confounding confounders. The evidence supporting use of heparin in peripheral arterial catheters comes mainly from one large (5139 patients) randomised trial including 198 sites in which various heparin dosing strategies were used. The limited evidence available suggests that use of heparin as an intermittent flush solution at a concentration of 10 U/ml in catheters locked between episodes of use is not beneficial. Use of heparin in peripheral arterial catheters will prolong their life and utility. Current evidence does not allow us to make firm conclusions regarding the benefit of adding heparin to the solutions infused continuously through peripheral venous catheters, but this intervention warrants further study.

Use of heparin in peripheral venous catheters

Our meta-analyses included three randomised controlled trials of intermittent heparin flushes and seven randomised controlled trials of continuous infusion of heparinised solution that were not included in the two previously published meta-analyses. Our finding that heparin at doses if 10 U/ml for intermittent flushing is no more beneficial than flushing with normal saline alone is in agreement with the results of these meta-analyses, which combined controlled and uncontrolled studies. This intervention has been evaluated in only four truly randomised controlled, double blind trials including a total of 652 catheters. These trials involved different populations and evaluated different outcomes. Added to the larger number of uncontrolled studies, however, the weight of the evidence supports discontinuation of use of 10 U/ml heparin flush in intermittent intravenous infusion devices.

Heparin at 100 U/ml used as an intermittent flush solution in locked catheters may increase catheter patency and may decrease catheter related phlebitis. The usual heparin dose of 10 U/ml was established from a study in dogs, and, although later studies confirmed the safety of this dose, the efficacy in maintaining catheter patency was not established. The safety and efficacy of heparin concentrations of 100 U/ml used as an intermittent flush needs further study on a wider variety of patients; the study showing a significant benefit for increasing patency and decreasing phlebitis was in obstetric patients with 18 gauge catheters for serial phlebotomy and the other trial in

<table>
<thead>
<tr>
<th>Author</th>
<th>Heparin</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashton et al</td>
<td>10 U 12 hourly</td>
<td>1.00 (0.02 to 47.56)</td>
</tr>
<tr>
<td>Craig et al, 1991</td>
<td>10 U 8 hourly</td>
<td>1.23 (0.81 to 1.86)</td>
</tr>
<tr>
<td>Kleiber et al, 1993</td>
<td>10 U 8 hourly</td>
<td>0.85 (0.47 to 1.52)</td>
</tr>
<tr>
<td>Common relative risk</td>
<td></td>
<td>1.09 (0.77 to 1.52)</td>
</tr>
<tr>
<td>Hamilton et al, 1988</td>
<td>100 U 8 hourly</td>
<td>0.68 (0.46 to 0.99)</td>
</tr>
<tr>
<td>Meyer et al, 1995</td>
<td>100 U 6 hourly</td>
<td>0.15 (0.02 to 1.17)</td>
</tr>
<tr>
<td>Common relative risk</td>
<td></td>
<td>0.61 (0.42 to 0.88)</td>
</tr>
<tr>
<td>Sketch et al, 1972</td>
<td>1 U/ml infusion</td>
<td>0.68 (0.35 to 1.29)</td>
</tr>
<tr>
<td>Danieli et al, 1973</td>
<td>1 U/ml infusion</td>
<td>0.60 (0.41 to 0.89)</td>
</tr>
<tr>
<td>Tanner et al, 1980</td>
<td>1 U/ml infusion</td>
<td>0.16 (0.05 to 0.49)</td>
</tr>
<tr>
<td>Alpan et al, 1984</td>
<td>1 U/ml infusion</td>
<td>0.33 (0.14 to 0.79)</td>
</tr>
<tr>
<td>Messing et al, 1991</td>
<td>1 U/ml infusion</td>
<td>0.44 (0.19 to 1.01)</td>
</tr>
<tr>
<td>Mocklair et al, 1991</td>
<td>1 U/ml infusion</td>
<td>1.17 (0.26 to 5.19)</td>
</tr>
<tr>
<td>Wright et al, 1995</td>
<td>1 U/ml infusion</td>
<td>0.75 (0.52 to 1.08)</td>
</tr>
<tr>
<td>Common relative risk</td>
<td></td>
<td>0.55 (0.39 to 0.77)</td>
</tr>
</tbody>
</table>

Fig 3 Relative risks (95% confidence intervals) of phlebitis from peripheral venous catheters according to treatment with or without heparin. Last two columns are numbers of catheters associated with phlebitis/total number of catheters.
a more variable population of adult medical patients lost 3.4% during follow up.15

Phlebitis is associated with duration of catheter patency because red inflamed catheter sites lead to early discontinuation. Continuously infused heparinised solutions may prolong patency because they significantly decrease the risk of phlebitis. The type of solution being infused is related to the risk of phlebitis. In newborn infants with 24 gauge catheters the duration of catheter patency is prolonged, and infiltration rates are decreased with use of 10 U/ml heparin in normal saline in catheters locked between use versus 10% dextrose by continuous infusion (no added heparin).16 Regular changing of the catheter has been advocated as an intervention to prevent phlebitis and clot formation, but in adult patients changing the heparin lock every 72 hours was shown to be of no benefit compared with leaving the catheter in place for up to 168 hours.17

Use of heparin in peripheral arterial catheters

Mostly on the basis of the results of one multicentre study heparin has been shown effectively to prolong the life of peripherally placed arterial pressure monitoring devices. The minimal effective dose of heparin, however, has not been established. Bolgiano et al reported no significant difference in duration of arterial catheter patency when heparin was used at 0.25 U/ml versus 1 U/ml in adults.18 Butt et al reported that increasing the heparin concentration from 1 U/ml to 5 U/ml in 22 gauge catheters in children significantly prolonged arterial catheter patency.19 The type of solution, however, may be important as Rais-Bahrami et al reported that neonatal peripheral arterial lines infused continuously with heparinised normal saline functioned significantly longer (107 (SD 71) hours) than those with heparinised 5% dextrose (59 (32) hours).20 Other agents besides heparin have also been shown to be effective in prolonging the duration of patency of radial arterial catheters. Arterial catheter solutions containing papaverine21 and 1.4% sodium citrate22 effectively prolong the duration of catheter patency and their risk profile should be compared with that of heparin.

Conclusions

In this systematic review we have clarified that low dose heparin is beneficial for maintaining peripherally placed arterial catheters when added to the continuously infused solutions. Heparin at a concentration of 1 U/ml infused continuously through peripheral venous catheters is a promising intervention to prolong catheter life but requires further study. While the use of 100 U/ml of intermittent heparin flushes for peripheral intravenous catheters needs further evaluation, evidence currently available suggests that the current use of 10 U/ml as an intermittent flush is no more effective than normal saline flush.

We thank Derek King for statistical assistance. DJC is a career scientist of the Ontario Ministry of Health.

Contributors: AGR formulated the idea for this systematic review, searched the literature, extracted the data, analysed the data, and wrote the paper. DJC helped with the data analysis and with interpreting and presenting results in the manuscript. CAG helped with literature searching and data abstraction. MA helped with preparing the manuscript and interpreting the data. AGR is guarantor for the study.

Key messages

- Despite almost universal use, agreement has not been reached on the need to administer heparin through peripheral intravascular catheters
- The results of 13 trials on peripheral venous catheters and two trials on peripheral arterial catheters were critically appraised to clarify what evidence supports the use of heparin
- Flushing peripheral venous catheters locked between use with heparinised saline at 10 U/ml is no more beneficial than flushing with normal saline
- Heparin significantly prolongs the duration of arterial catheter patency and decreases the risk of clot formation
- In peripheral venous catheters heparin added to the infusion at 1 U/ml decreases phlebitis and may prolong duration of catheter patency and decrease infusion failure

Funding: National Research Service Award F32 HS0106-01 from the Agency for Health Care Policy and Research (AGR).

Conflict of interest: None.

5 American Society of Hospital Pharmacists. ASHP therapeutic position statement on the institutional use of 0.9% sodium chloride injection to maintain the patency of peripheral indwelling infusion devices. *Am J Hosp Pharm* 1994;51:1574-4.


BMJ: first published as 10.1136/bmj.316.7136.969 on 28 March 1998. Downloaded from http://www.bmj.com by guest. Published by BMJ Publishing Group Ltd. Protected by copyright.
Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and Republic of Ireland

A Metin Gülmezoglu, Lelia Duley

Pre-eclampsia is a multisystem disorder associated with hypertension and proteinuria and is a fairly common complication of pregnancy. Eclampsia, the occurrence of convulsions (pre-eclampsia) is rare, but both conditions can have serious consequences for the mother and infant. Anticonvulsants are given to women with eclampsia to prevent further fits and to women with pre-eclampsia to prevent the first fit, thereby improving the outcome for mother and infant. Clinical practice, however, varies greatly worldwide. In the United Kingdom diazepam has been popular since the 1970s and phenytoin since the early 1990s, but the use of magnesium sulphate remains uncommon. Magnesium sulphate has been widely used for decades in the United States and has recently been acknowledged as the preferred anticonvulsant for women with eclampsia. There is little evidence to support or refute the use of anticonvulsants in women with pre-eclampsia. We conducted a survey to determine the current use of anticonvulsants in eclampsia and pre-eclampsia.

Subjects, methods, and results

A questionnaire was sent to consultants in the United Kingdom and the Republic of Ireland asking about their use of anticonvulsants in women with eclampsia or pre-eclampsia. Two reminders were sent six weeks apart.

The table summarises the main results. Of the 662 respondents who used prophylactic anticonvulsants, 658 were more likely to prescribe them in the presence of signs or symptoms of imminent eclampsia and 364 would consider using an anticonvulsant if delivery was unlikely within the next 24 hours. Over half (475) of the respondents would collaborate in a placebo controlled trial of magnesium sulphate versus placebo in women with eclampsia.

Comment

Compared with earlier surveys, our survey was shorter and simpler and focused largely on anticonvulsant use. Our survey also had a slightly better response rate (table). Since 1991, when the last survey was conducted, the reported use of magnesium sulphate in pre-eclampsia has risen from 2% to 40%. During 1992 only 2% of women with eclampsia received magnesium sulphate, whereas 60% of respondents in our survey said that they would now use this anticonvulsant for such women. As the use of magnesium sulphate had remained at 2% for 14 years, this change probably occurred after publication of evidence showing that magnesium sulphate is better than diazepam or phenytoin for eclampsia. Despite this substantial shift in practice, diazepam remains the most widely used anticonvulsant for pre-eclampsia and eclampsia, and phenytoin continues to be used by a quarter of respondents. We believe that magnesium sulphate should be used in preference to diazepam and phenytoin.

National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford OX2 6HE
A Metin Gülmezoglu, research fellow
Lelia Duley, senior research fellow
Correspondence to: Dr AM Gülmezoglu, United Kingdom Cochrane Centre, NHS Research and Development Programme, Summertown Pavilion, Oxford OX2 7LG mgulmezoglu@cochrane.org.uk

BMJ 1998;316:975-6


Stremling JR. Heparin and infusion phlebitis. BMJ 1978;ii:105-6


Epperson EL. Efficacy of 0.9% sodium chloride injection with and without heparin for maintaining indwelling intermittent injection sites. Clin Pharm 1984;3:626-9


Carrell JS, LaRocca J, Ast D, Smith DF, Sweet DE. Comparison of heparin and 0.9% sodium chloride injection in the maintenance of indwelling intermittent infusion devices. Clin Pharm 1989;8:34-9

Jowett NL, Stephens JM, Thompson DR, Sutton DW. Do indwelling cannulae on coronary care units need a heparin flush? Intens Care Nurs 1986;2:16-9


25 Stremling JR. Heparin and infusion phlebitis. BMJ 1978;ii:105-6


28 Epperson EL. Efficacy of 0.9% sodium chloride injection with and without heparin for maintaining indwelling intermittent injection sites. Clin Pharm 1984;3:626-9


31 Garrels JC, LaRocca J, Ast D, Smith DF, Sweet DE. Comparison of heparin and 0.9% sodium chloride injection in the maintenance of indwelling intermittent infusion devices. Clin Pharm 1989;8:34-9

32 Jowett NL, Stephens JM, Thompson DR, Sutton DW. Do indwelling cannulae on coronary care units need a heparin flush? Intens Care Nurs 1986;2:16-9


37 Mathlouthi RR, Roush DR, Rapp RF, Foster TS, Mazarella V, McKean HE. Double-blind study to investigate methods to prevent cephalothin-induced phlebitis. Am J Hosp Pharm 1977;34:29-34


39 Hanson RL, Grant AM, Majors KR. Heparin lock maintenance with ten units of sodium heparin in one milliliter of normal saline solution. Surg Gynec Obstet 1976;143:273-6


46 Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 1995;103:882-5

(Accepted 27 November 1997)